Methods in Neuroepidemiology
Thrombolysis in Acute Childhood Stroke: Design and Challenges of the Thrombolysis in Pediatric Stroke Clinical TrialAmlie-Lefond C.a · Chan A.K.C.d · Kirton A.e · deVeber G.f · Hovinga C.A.b · Ichord R.c · Stephens D.f · Zaidat O.O.a
aDepartment of Neurology, Medical College of Wisconsin, Milwaukee, Wisc., bDepartments of Clinical Pharmacy and Pediatrics, University of Tennessee Health Science Center, Memphis, Tenn., and cDepartment of Neurology and Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, Pa., USA; dDepartment of Pediatrics, McMaster University, Hamilton, Ont., eDepartment of Pediatrics and Clinical Neuroscience, University of Calgary, Calgary, Alta., and fDepartment of Neurology, Hospital for Sick Children, Toronto, Ont., Canada
Catherine Amlie-Lefond, MD
Medical College of Wisconsin, Department of Neurology
9200 W Wisconsin Ave
Milwaukee, WI 53226 (USA)
Tel. +1 414 266 7545, Fax +1 414 266 3466, E-Mail Klefond@mcw.edu
Do you have an account?
Background: Although tissue plasminogen activator (tPA) has revolutionized the treatment of acute ischemic stroke in adults, no thrombolysis trials in childhood stroke have been conducted. Experience in adults cannot be applied to children due to fundamental age-related differences in coagulation systems, stroke pathophysiology and neuropharmacology. Obstacles to acute treatment trials in childhood stroke include delays in diagnosis and minimizing risk in a vulnerable population. Study Design: Thrombolysis in Pediatric Stroke (TIPS) is an international multicenter study to assess the safety of intravenous tPA within 0–3 h and intra-arterial tPA within 3–6 h of onset of arterial ischemic stroke in childhood. Through the International Pediatric Stroke Study, 30 international centers will enroll a total of 48 patients: 24 will be treated with intravenous tPA (0.6, 0.75, 0.9, and 1.0 mg/kg) using the classical dose-finding method, and 24 will be treated with intra-arterial tPA (maximum 0.2, 0.3, 0.4, and 0.5 mg/kg) using a Bayesian dose-finding method. Conclusion: The TIPS trial will be the first clinical trial exploring the safety and feasibility of systemic and local thrombolytic therapy in childhood stroke and the obstacles in conducting such a trial.
© 2009 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.